Hangzhou Biotest Faces Valuation Challenges Amid Declining Sales and Profitability

Hangzhou Biotest Biotech Co., Ltd., a midcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in evaluation. This revision reflects a notable shift in the company's valuation metrics, which are critical indicators of its market position and financial health. The company's P/E ratio stands at 54, suggesting a premium valuation compared to industry norms. Additionally, the Price to Book Value is recorded at 2.32, while the EV to EBIT and EV to EBITDA ratios are significantly high at 79.77 and 58.72, respectively. These figures indicate a complex financial landscape for Hangzhou Biotest, particularly in light of its recent performance indicators. The company has reported a decline in net sales, with an annual growth rate of -38.86% over the past five years, and a significant drop of -13.84% in the most recent quarter. Furthermore, the net profit for the quarter was CNY 9.86 million, reflecting a decrease of -42.12%. The debt-equity ratio has also reached a concerning level of -65.15%, and the debtors turnover ratio is at its lowest, recorded at 5.54 times. These trends contribute to the overall evaluation adjustment for Hangzhou Biotest Biotech Co., Ltd., highlighting the challenges the company faces in the current market environment. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.